Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has a collaborative research program with Patrys Limited and The University of Sydney. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.